Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT04368689 (FLOAT) for Post-Traumatic Stress Disorders is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD (FLOAT) 30
Clinical Trial NCT04368689 (FLOAT) is an interventional study for Post-Traumatic Stress Disorders that is active, not recruiting. It started on June 18, 2021 with plans to enroll 30 participants. Led by Medical College of Wisconsin, it is expected to complete by December 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 21, 2026.
Brief Summary
This project is being done to explore the effects floating has on individuals who have a history of trauma with stress related symptoms.
Detailed Description
This pilot study looks to further the current floatation-based REST literature by exploring the therapy's effectiveness within a community-based sample of adults with PTSD. This type of sample allows the study the opportunity to recruit both veteran and civilian subjects, two populations that can suffer from this clinical diagnosis and stand to benefit from this therapy. This study will:
- Evaluate the psychologica...
Official Title
The Feasibility and Examination of the Effects of Floatation-based Reduced Environmental Stimulation Therapy (REST) on a Community Sample With Posttraumatic Stress Disorder (PTSD)
Conditions
Post-Traumatic Stress DisordersPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- FLOAT
- PRO00032660
NCT ID Number
Start Date (Actual)
2021-06-18
Last Update Posted
2026-01-21
Completion Date (Estimated)
2027-12
Enrollment (Estimated)
30
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Floatation-based Reduced Environmental Stimulation Therapy
PTSD
FLOAT
Trauma
PTSD
FLOAT
Trauma
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalFloating Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart. | Floatation-based Reduced Environmental Stimulation Therapy Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart |
Primary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Post Traumatic Stress Disorder (PTSD) symptom severity score as measured by Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) A clinician-administered structured diagnostic interview that is considered the gold standard for assessing and diagnosing PTSD. | Baseline, week 2, week 3 |
Change in Post Traumatic Stress Disorder (PTSD) symptom severity score as measured by PTSD Checklist for DSM-5 | PTSD Checklist for DSM-5 The PCL-5 consists of 20 items and it takes 5 to 10 minutes to administer. Participants are instructed to answer items based on their experience of symptoms since the trauma (hospitalization) or in the last month (1 month). Each item corresponds to a symptom in the DSM-5. | Baseline, week 2, week 3 |
Change in depression symptom severity score as measured by the Center for Epidemiologic Studies Depression Scale - Revised | Center for Epidemiologic Studies Depression Scale - Revised Diagnostic tool for criteria for a major depressive episode | Baseline, week 2, week 3 |
Change in depressive symptom severity score as measured by Patient Health Questionnaire (PHQ-9) | Patient Health Questionnaire (PHQ-9) The PHQ-9 is a 9-Item measure for assessing the severity of depressive symptoms over the past 2 weeks. Scores of 1-4 are considered indicative of minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. | Baseline, week 2, week 3 |
Change in stress symptom score | Perceived Stress Scale The Perceived Stress Scale is a psychological instrument used for measuring an individual's perception of stress. | Baseline, week 2, week 3 |
Change in Sheehan Disability Scale score | Sheehan Disability Scale How much mental health issues have affected their daily activities: work/school, social/leisure activities, and family life/home responsibilities. Total disability scores range between 0 to 30, with scores ≥ 5 signifying impairment. | Baseline, week 2, week 3 |
Change in perceived happiness score | Fordyce Happiness Measure Measures emotional well being by perceived happiness | Baseline, week 2, week 3 |
Change in anxiety symptom severity score | State-Trait Anxiety Inventory 20-item self-report questionnaire designed to assess an individual's level of anxiety. | Baseline, week 2, week 3 |
Change in Positive and Negative Affect | Positive and Negative Affect Schedule - Expanded Form 20-items survey assessing general states of positive and negative affect using on a 5 point scale | Baseline, week 2, week 3 |
Change in present moment sleepiness | Karolinska Sleepiness Scale Single item measure of present moment sleepiness | Baseline, week 2, week 3 |
Change in pain score | Wong-Baker Pain scale Rates current level of pain from 0 to 10. | Baseline, week 2, week 3 |
Change in Visual Analogue Scales score | Visual Analogue Scales- Relaxation, Muscle tension, Content/Peaceful, Refreshed, Energy \& Overall Well-Being 7 measures rating on a 100-point scale and assessing overall well-being using a bipolar valence scale that goes from "Pretty Bad" to "Pretty Good" | Baseline, week 2, week 3 |
Change in Side effect checklist score | Side effect checklist 43-item side effect checklist to assess the safety of Floatation- REST, and potential adverse experiences. | Baseline, week 2, week 3 |
Change in Skin Conductance response post float | Skin Conductance This will be measured using a program called "eSense". eSense (Mindfield Biosystems LLC), an ambulatory system for collecting skin conductance, or sweat gland activity. eSense samples skin conductance at 5 Hz, substantially lower than more traditional (and more expensive) laboratory systems. This will be done during the Trauma Narrative where subjects are asked to describe an event that they consider to be the most traumatic in their life including: who was there, what they were doing, where they were, how things looked, what they heard, etc. | Baseline, Week 2, week 3 |
Change in blood pressure post float | -Blood Pressure This will be measured using a blood pressure cuff. This is performed before and after each float. | Baseline, Week 2, week 3 |
Change in number of mental health disorder diagnostic criteria met | -Mini International Neuropsychiatric Interview - Depression (M.I.N.I. 7.0.2) The MINI is a short structured diagnostic interview designed to meet the need for a short but accurate psychiatric interview determining diagnostic criteria for 17 of the most common disorders in mental health. This version is for DSM-5 and ICD-10 diagnoses. The measure's psychometric properties of diagnostic validity and reliability have been determined to be strong | Baseline, Week 3 |
Anxiety sensitivity severity score pre float | -Anxiety Sensitivity Index (ASI-3) 18-item questionnaire using a 4-point scale and total ASI scores can range from 0 to 72. A meta-analysis \[46\] found that patient groups with anxiety and depression commonly have a total ASI score above 30, and other studies have used a cutoff score ≥ 30 to recruit individuals with very high levels of anxiety sensitivity. | Baseline |
Overall Anxiety Severity and Impairment score pre float | Overall Anxiety Severity and Impairment Scale A 5-item questionnaire that can be used across the different anxiety disorders as a continuous measure of anxiety severity and impairment over the past week. Each item is rated on a 5-point scale and the ratings are summed to obtain a total score ranging from 0 to 20. | Baseline |
Occurrence of adverse events post float | Debriefing Interview Occurrence of adverse events and qualitative information about floating. How was your float today? What did you think about while floating? Did anything surprise you? Did you learn anything about yourself?
Follow-up Questions At the end of your float, how did you feel about the duration? Wanted to get out before/Perfect amount of time/Wish I could have stayed longer.
Other techniques tried to help relax and feel less anxious and stressed? anti-anxiety medication/psychotherapy/massage/exercise/alcohol/breathing techniques/cigarettes/marijuana/progressive muscle relaxation/meditation/yoga/other Experience during and after today's float session compared to the other relaxation techniques tired? More relaxation with others/Equally as good as the others/More relaxation with floating than any others Interested in floating again in the future and thoughts on specialized pools being effective therapy for reducing symptom severity? Yes/No/Maybe | Week 3 |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
- Has posttraumatic stress disorder (PTSD) as confirmed by the PCL-5
- 18-60 years of age
- History of neurological conditions (e.g., epilepsy, stroke, severe traumatic brain injury, Parkinson's disease, Alzheimer's disease or other forms of dementia)
- Any skin conditions or open wounds that could cause pain when exposed to saltwater
- Has floated previously
- Has Schizophrenia spectrum or other psychotic disorders
- Refuses to adhere to the Pre-Float Checklist
- Non-English speaking
- Inability to lay comfortably in a shallow pool of water
- Refuses participation in the floatation-REST sessions
- Refuses to sign the Float Liability Waiver prior to floating
- No Communicable disease (e.g.- HIV, Hepatitis A, B& C, tuberculosis, or measles)
- No psychoactive drugs or laxatives within the past week from scheduled float. Psychoactive drugs include, but are not limited to: methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), psilocybin, peyote, phencyclidine, ketamine).No recreational drug use (e.g.tetrahydrocannabinol,abuse of prescription medicine) day before or day of study visit. No antihistamine that causes drowsiness and no alcohol the day of the float sessions.
- Lack of control of bodily functions prior to scheduled float
- Fresh tattoos that would inhibit ability to float (consult with tattoo artist)
- Colored/dyed hair less than one week old from scheduled float
- Body tanning/spay/paint less than one week old from scheduled float
- Active suicidal ideation
Study Responsible Party
Terri deRoon Cassini, Principal Investigator, Associate Professor, Medical College of Wisconsin
No contact data.
1 Study Locations in 1 Countries
Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin, 53226-3548, United States